GC012F, an autologous CAR-T candidate utilizing the proprietary FasTCAR next-day manufacturing platform, has shown promise in treating multiple myeloma and other hematological cancers. The company was acquired by AstraZeneca, transitioning from independent clinical-stage developer to part of a major pharmaceutical conglomerate's oncology portfolio. As of July 2026, the company is in transition following its acquisition completion.
Cyborg Score Rationale
Gracell operates a differentiated technology platform (FasTCAR/TruUCAR) addressing real CAR-T manufacturing pain points, validating its strategic rationale. However, as a clinical-stage company acquired by AstraZeneca with delisting from Nasdaq, it now operates as a private subsidiary without public capital markets visibility. Pipeline advancement and AZ integration will determine long-term value creation.
Top Insights
As of May 2026, Gracell maintained approximately CNY 1.71 billion in cash reserves while carrying CNY 182.98 million in debt, indicating capital availability for continued pipeline development.
Lead programs GC012F (dual BCMA/CD19 CAR-T for multiple myeloma in Phase I), GC019F (CD19-directed CAR-T for B-ALL in Phase I), GC027 (CD7-directed allogeneic CAR-T in Phase I), and GC007g (CD19-directed allogeneic CAR-T in Phase 1/2) span both autologous and allogeneic modalities addressing hematologic malignancies.
Acquisition by AstraZeneca was completed, with Gracell delisting from Nasdaq effective 10 days after Form 25 filing with the SEC and suspending US reporting obligations.
Named Competitors
Kite CAR-T therapies — Established CAR-T immunotherapy developer
Kymriah — CAR-T cell therapy for blood cancers and solid tumors
Allogene Therapeutics — Allogeneic CAR-T immunotherapy developer for oncology
CAR-T programs — Cell therapy company developing CAR-T and gene therapies
Recent Developments
(February 2024) Shareholders approved merger agreement with AstraZeneca and delisting from Nasdaq Global Select Market
(May 2026) Cash position of CNY 1.71 billion reported, indicating financial runway maintenance
(2024) Completion of AstraZeneca acquisition and transition to private subsidiary status
Open the full interactive Gracell Biotechnologies Inc. report
Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.